Back to Search
Start Over
Correction to: A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial.
- Source :
- Trials; 12/14/2020, Vol. 21 Issue 1, p1-1, 1p
- Publication Year :
- 2020
-
Abstract
- An amendment to this paper has been published and can be accessed via the original article. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 17456215
- Volume :
- 21
- Issue :
- 1
- Database :
- Complementary Index
- Journal :
- Trials
- Publication Type :
- Academic Journal
- Accession number :
- 147605561
- Full Text :
- https://doi.org/10.1186/s13063-020-04947-2